Mucopolysaccharidoses and oligosaccharidoses

A three-year-old who seemed entirely well as a baby is brought in because the face has thickened, the words have slowed, and the herniae never closed. The general practitioner mentions large tonsils, snoring, and a heart murmur. Across the corridor, a six-year-old with striking short-trunk dwarfism and perfectly preserved intellect is referred after a near-miss at intubation for dental work. In both rooms the unifying question is the same: which lysosomal hydrolase is missing, which glycosaminoglycan is accumulating, and is the brain involved. The fellowship task is to reason from the coarse-facies pattern to the substrate, the enzyme, and the treatment — before the airway, the cervical cord, or the cognition is lost. ^{[1] [2]}

Overview & Definition

The mucopolysaccharidoses are a family of inherited metabolic diseases in which a deficient lysosomal enzyme blocks the stepwise degradation of glycosaminoglycans — the long, sulphated sugar chains once called mucopolysaccharides that make up much of connective tissue, cartilage, and the extracellular matrix. When a single cleavage step fails, the partially degraded chain accumulates inside the lysosome and the cell distends, malfunctions, and dies. The stored material, not the missing enzyme per se, drives the visible phenotype, which is why a Hurler macrophage engorged with dermatan and heparan sulfate looks and behaves differently from a neuron in Sanfilippo swollen with heparan sulfate alone. ^{[1] [9]}

The oligosaccharidoses — sometimes called glycoproteinoses — sit in the same clinical space but store the sugar chains stripped from glycoproteins rather than free glycosaminoglycans. Alpha-mannosidosis, fucosidosis, the sialidoses, aspartylglucosaminuria, and the mucolipidoses (including I-cell disease) share the coarse facies, dysostosis multiplex, and variable neurodegeneration of the mucopolysaccharidoses, and they are screened for on the same urine metabolic panel. Grouping them together is not a taxonomic pedantry: it reflects the reality that a single urine test and a single enzyme-assay strategy covers both families, and that the coarse-facies differential at the bedside spans both. ^{[2] [6]}

The inheritance matters because it changes counselling and screening. All the mucopolysaccharidoses except Hunter (MPS II) are autosomal recessive, so a previously affected child reshapes the reproductive risk for every subsequent pregnancy and makes carrier testing and prenatal diagnosis central to management. Hunter syndrome is X-linked recessive, so affected boys present with disease and carrier mothers may show attenuated features, and the screening of at-risk maternal males becomes part of the family workup. Naming the inheritance at the first consultation frames every later conversation about siblings, future children, and the wider family. ^{[1] [4]}

References12ShowHide

1. [1]Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford), 2011.PMID 22210669
2. [2]Wraith JE. Mucopolysaccharidoses and mucolipidoses. Handb Clin Neurol, 2013.PMID 23622395
3. [3]Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. Pediatrics, 2007.PMID 17671068
4. [4]Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med, 2006.PMID 16912578
5. [5]Akyol MU, Alden TD, Amartino H, et al. Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance. Orphanet J Rare Dis, 2019.PMID 31196221
6. [6]Malm D, Nilssen O. Alpha-mannosidosis. Orphanet J Rare Dis, 2008.PMID 18651971
7. [7]David-Vizcarra G, Briody J, Ault J, et al. The natural history and osteodystrophy of mucolipidosis types II and III. J Paediatr Child Health, 2010.PMID 20367762
8. [8]Caciotti A, Melani F, Tonin R, et al. Type I sialidosis, a normosomatic lysosomal disease, in the differential diagnosis of late-onset ataxia and myoclonus: an overview. Mol Genet Metab, 2020.PMID 31711734
9. [9]Platt FM, d'Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal storage diseases. Nat Rev Dis Primers, 2018.PMID 30275469
10. [10]Matern D, Gavrilov D, Oglesbee D, Raymond K, Rinaldo P, Tortorelli S. Newborn screening for lysosomal storage disorders. Semin Perinatol, 2015.PMID 25891428
11. [11]Gentner B, Tucci F, Galimberti S, et al. Hematopoietic stem- and progenitor-cell gene therapy for Hurler syndrome. N Engl J Med, 2021.PMID 34788506
12. [12]Parini R, Deodato F Intravenous enzyme replacement therapy in mucopolysaccharidoses: clinical effectiveness and limitations. Int J Mol Sci, 2020.PMID 32340185